It has no published human trials
See should copper peptides be refrigerated and GHK-Cu shelf life for product storage during cycling
We confirm that while KA acts as a mixed inhibitor, HQ can act both as a TyrBm substrate and as an inhibitor
Furthermore, the integration of RNA therapeutics with small-molecule agents or gene-editing technologies (such as CRISPR-Cas systems) might augment the functional stability of RNA-based therapies, resulting in synergistic anticancer effects
If we can figure out those molecules and enhance them through diet, exercise, nutrition, supplementation, or medications to replace what were missing, thats the ultimate goal
doi:10.1016/S0006-8993(98)01098-1